Protective SARS-CoV-2 Antibody Response in Children With Inflammatory Bowel Disease.

ABSTRACT:

Background

To date, there's no evidence of an increased risk of SARS-CoV-2 infection or more severe COVID-19 in patients with inflammatory bowel disease (IBD). However, whether COVID-19 alters the clinical course of IBD or whether IBD treatment affects the immunological response to SARS-CoV-2 is still under investigation, especially in children.

Aim

To assess the serological response to SARS-CoV-2 in children with IBD, and to evaluate the impact of COVID-19 on the clinical course of IBD.

Material and methods

This prospective study enrolled children (0-18 years) followed-up at the University Hospital of Padova for IBD, who acquired a confirmed SARS-CoV-2 infection between 02.2020 and 02.2021. The anti-SARS-CoV-2 S-RBD IgG titer was evaluated at 3 months after infection

SUBMITTER: Bosa L 

PROVIDER: S-EPMC8866952 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature